Rajangam Kanya — SEC insider filings
SEC reporting owner CIK 1816676. 15 insider filings on record with FilingPulse; latest filed 2026-10-23.
Transaction summary — filings shown
Covers all 15 filings on record, filed 2021-01-12 to 2026-10-23. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 3 legs across 2 filings — 11,479 shares, $378,874 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 20.
- Largest priced transaction: sale of 10,000 shares @ $37.28 ($372,800) in Nkarta, Inc., filed 2021-08-09.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Nkarta, Inc. (NKTX) | Chief Medical Officer | 3 | — | 1 leg · 10,000 sh · $372,800 | 5 |
| Senti Biosciences Holdings, Inc. (SNTI) | Pres. & Chief Med. & Dev. Off. | 10 | — | 2 legs · 1,479 sh · $6,074 | 13 |
| Turnstone Biologics Corp. (TSBX) | Director | 2 | — | — | 2 |
Insider filings — Rajangam Kanya
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-23 | 4 | Senti Biosciences Holdings, Inc. (SNTI) | Tax withholding (F): 19,953 @ $0 | EDGAR |
| 2026-03-11 | 4 | Senti Biosciences, Inc. (SNTI) | Tax withholding (F): 10,757 @ $0 | EDGAR |
| 2026-02-03 | 4 | Senti Biosciences, Inc. (SNTI) | Tax withholding (F): 1,384 @ $0 | EDGAR |
| 2025-03-11 | 4 | Senti Biosciences, Inc. (SNTI) | Conversion (C): 33,000 @ $2.25 · Conversion (C): 33 (derivative) @ $2,250 | EDGAR |
| 2025-03-10 | 4 | Senti Biosciences, Inc. (SNTI) | Grant/award (A): 78,363 @ $0 · Grant/award (A): 235,088 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | Senti Biosciences, Inc. (SNTI) | Sale (S): 1,297 @ $4.07 · Sale (S): 182 @ $4.37 | EDGAR |
| 2024-12-10 | 4 | Senti Biosciences, Inc. (SNTI) | Grant/award (A): 33 (derivative) @ $2,250 · Grant/award (A): 49,500 (derivative) @ $0 | EDGAR |
| 2024-07-02 | 4 | Turnstone Biologics Corp. (TSBX) | Grant/award (A): 12,770 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | Senti Biosciences, Inc. (SNTI) | Grant/award (A): 101,000 @ $0 · Grant/award (A): 152,000 (derivative) @ $0 | EDGAR |
| 2023-10-17 | 4 | Turnstone Biologics Corp. (TSBX) | Grant/award (A): 8,012 (derivative) @ $0 | EDGAR |
| 2023-02-02 | 4 | Senti Biosciences, Inc. (SNTI) | Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2022-07-20 | 4 | Senti Biosciences, Inc. (SNTI) | Grant/award (A): 327,750 (derivative) @ $0 | EDGAR |
| 2022-01-19 | 4 | Nkarta, Inc. (NKTX) | Grant/award (A): 12,800 @ $0 · Grant/award (A): 76,800 (derivative) @ $0 | EDGAR |
| 2021-08-09 | 4 | Nkarta, Inc. (NKTX) | Option exercise (M): 10,000 @ $0.41 · Sale (S): 10,000 @ $37.28 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2021-01-12 | 4 | Nkarta, Inc. (NKTX) | Grant/award (A): 52,500 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-01-06 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1816676 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs